Health & Environmental Research Online (HERO)


Print Feedback Export to File
2740912 
Journal Article 
Hazards of interferon therapy for HBV-seronegative chronic hepatitis 
Vento, S; Di Perri, G; Garofano, T; Cosco, L; Bassetti, D; Et al 
1989 
1 
The Lancet
ISSN: 0140-6736
EISSN: 1474-547X 
IPA/90/882290 
VOL 2 ISS Oct 14 1989 
REF 6 
English 
IPA COPYRIGHT: ASHP Exacerbations of autoimmune chronic active hepatitis are reported in 2 patients (aged 17 and 49 yr) misdiagnosed as having NANB hepatitis who were treated with recombinant alpha2a-interferon and alpha2b-interferon, respectively, starting at a dose of 3 MU 3 times/wk. After 4-6 wk, interferon therapy was discontinued but the patients showed no clinical improvement. Steroid therapy was started and later the patients were discharged on maintenance therapy. Histological examination of the liver later showed inactive chronic hepatitis. It was suggested that a test for NANB hepatitis should be performed before interferon treatment is started.